Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Phase 2
Terminated
- Conditions
- Hormone-Resistant Prostate CancerMetastatic Prostatic AdenocarcinomaProstate AdenocarcinomaRecurrent Prostate Carcinoma
- Interventions
- Procedure: Biopsy of ProstateOther: Laboratory Biomarker Analysis
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01253642
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01228084
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
Phase 1
Withdrawn
- Conditions
- Primary Peritoneal CarcinomaOvarian Carcinoma, Stage 3 or 4Epithelial Ovarian Carcinoma
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT01138137
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Phase 1
Terminated
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificBreakthrough Nausea and Vomiting
- Interventions
- Drug: systemic chemotherapyOther: survey administrationProcedure: quality-of-life assessment
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT01031953
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01005914
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response
Terminated
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00994201
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase 1
- Conditions
- Germ Cell TumorRecurrent MedulloblastomaEmbryonal Tumor With Multilayered Rosettes, C19MC-AlteredMedulloblastomaMedulloepitheliomaRecurrent Malignant Germ Cell TumorRecurrent Primitive Neuroectodermal TumorPrimitive Neuroectodermal TumorCentral Nervous System Embryonal NeoplasmRecurrent Childhood Central Nervous System Embryonal Neoplasm
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00983398
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
Early Phase 1
Completed
- Conditions
- Recurrent Childhood Brain NeoplasmChildhood Brain Neoplasm
- Interventions
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingProcedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00978562
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Tissue Sample Collection From Patients With Fanconi Anemia
Completed
- Conditions
- Fanconi AnemiaUnspecified Childhood Solid Tumor, Protocol SpecificUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT00899522
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Terminated
- Conditions
- LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsBreast CancerGestational Trophoblastic TumorNausea and VomitingOvarian CancerChronic Myeloproliferative DisordersLymphomaMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00900068
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath